Figure 3
Figure 3. Design and structure of UHRA compounds and efficacy in blocking thrombin binding to polyP. (A) Representative structure of a typical UHRA scaffold (in this case, for UHRA-10) containing a dendritic polyglycerol core bearing the randomly distributed polyP-binding groups (R) and an outer shell of short-chain polyethylene glycols. The molecular weight and number of R groups was varied to generate the other UHRAs. (B) Fifty percent inhibitory concentration (IC50) values for the ability of 16 UHRA compounds to inhibit thrombin binding to immobilized polyP. Arrows indicate the 4 compounds selected for further study: UHRA-8 (R = 24; 23 kDa), UHRA-9 (R = 16; 16 kDa), UHRA-10 (R = 11; 10 kDa), and UHRA-14 (R = 7; 10 kDa).

Design and structure of UHRA compounds and efficacy in blocking thrombin binding to polyP. (A) Representative structure of a typical UHRA scaffold (in this case, for UHRA-10) containing a dendritic polyglycerol core bearing the randomly distributed polyP-binding groups (R) and an outer shell of short-chain polyethylene glycols. The molecular weight and number of R groups was varied to generate the other UHRAs. (B) Fifty percent inhibitory concentration (IC50) values for the ability of 16 UHRA compounds to inhibit thrombin binding to immobilized polyP. Arrows indicate the 4 compounds selected for further study: UHRA-8 (R = 24; 23 kDa), UHRA-9 (R = 16; 16 kDa), UHRA-10 (R = 11; 10 kDa), and UHRA-14 (R = 7; 10 kDa).

Close Modal

or Create an Account

Close Modal
Close Modal